I've listed
the newer biologics. Already I've marked some red as there haven't been new
studies or an old study had been presented. I have already gone into detail
concerning Mavrilimumab, SAN-300, and Tregalizumab. I'll have a look at other
compounds soon.
Links:
Tregalizumab http://rheumatologe.blogspot.de/2014/01/tregalizumab-at-acr-2013-meeting-in-san.html
No comments:
Post a Comment